EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy

Jianqi Zhao iD, Guangyao Liu, Xiao Shi, Chunhong Huang iD

Toxins · 2025

DOI: 10.3390/toxins17060280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Jianqi Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 30006, Jiangxi, China. Hauptthemen laut MEDLINE: Antivenins, Quercetin, Snake Bites, Metalloproteases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Key Project of Natural Science Foundation of Jiangxi Province, Key Project of Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Snakebite is a significant global public health challenge, and the limited application of antivenom has driven the exploration of novel therapies. Combination therapy using small-molecule drugs targeting phospholipases A2 (PLA2) and metalloproteinases (SVMP) in venom shows great potential. Although Rhamnetin and RXP03 exhibit notable anti-phospholipase and anti-metalloproteinase activities, respectively, their antiophidic potential remains poorly explored. This study aims to evaluate the inhibitory effects of Rhamnetin and RXP03 on snake venom toxicity. Methodologically, we conducted in vitro enzymatic assays to quantify PLA2/SVMP inhibition, murine models of envenomation (subcutaneous/intramuscular venom injection) to assess local tissue damage and systemic toxicity, and histopathological/biochemical analyses. In vitro experiments demonstrated that Rhamnetin effectively inhibited PLA2 activity while RXP03 showed potent suppression of SVMP activity, with their combination significantly reducing venom-induced hemorrhagic activity. In murine models, the combined therapy markedly alleviated venom-triggered muscle toxicity and ameliorated oxidative stress. Furthermore, the combination enhanced motor performance and survival rate in mice, improved serum biochemical parameters, corrected coagulation disorders, and attenuated pathological damage in liver, kidney, heart, and lung tissues. This research demonstrates that dual-targeted therapy against metalloproteinases and phospholipases in snake venom can effectively prevent a series of injuries caused by snake venom. Collectively, the combined application of Rhamnetin and RXP03 exhibits significant inhibitory effects on a variety of venom-induced toxicities, providing pharmacological evidence for the development of antivenom therapies. However, the efficacy validation in this study was limited to murine models, and there is a discrepancy with clinical needs for delayed treatment in real-world envenomation scenarios. Despite these limitations, the findings provide robust preclinical evidence supporting the Rhamnetin–RXP03 combination therapy as a cost-effective, broad-spectrum antivenom strategy. Future studies are required to optimize dosing regimens and evaluate clinical translatability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiveninsQuercetinSnake BitesMetalloproteasesPhospholipase A2 InhibitorsAnimalsMaleMiceDisease Models, AnimalDrug Therapy, CombinationPhospholipases A2

Stichwörter der Autor:innen

RXP03Rhamnetinantivenom drugssmall molecule inhibitorssnake venom

Substanzen

AntiveninsQuercetinMetalloproteasesPhospholipase A2 InhibitorsPhospholipases A2

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 30006, Jiangxi, China.
  • The First Clinical Medical College, Nanchang University, Nanchang 330047, China.
  • Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi, China.

ORCID-Profile: Jianqi Zhao, Chunhong Huang

Förderung

  • National Natural Science Foundation of China
  • the Key Project of Natural Science Foundation of Jiangxi Province
  • Key Project of Natural Science Foundation of Jiangxi Province

Zitieren

APA

Zhao, J., Liu, G., Shi, X., & Huang, C. (2025). Combination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy. Toxins. https://doi.org/10.3390/toxins17060280

Vancouver

Zhao J, Liu G, Shi X, Huang C. Combination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy. Toxins. 2025. doi:10.3390/toxins17060280

BibTeX
@article{Zhao2025,
  author = {Zhao, Jianqi and Liu, Guangyao and Shi, Xiao and Huang, Chunhong},
  title = {Combination of Rhamnetin and RXP03 Mitigates Venom-Induced Toxicity in Murine Models: Preclinical Insights into Dual-Target Antivenom Therapy},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17060280}
}
Kostenlos starten →